KDR and renal carcinoma: Hypothyroidism has been reported in sorafenib-treated patients with renal cancer and sunitinib-treated patients with gastrointestinal stromal cancer [28,29], and anti-VEGF or anti-VEGFR2 treatment induced vascular regression in the thyroid and decreased plasma thyroid hormone levels in mice [30].